- Home
- DOMH vs TCRX Comparison
DOMH vs TCRX Comparison
Compare DOMH & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOMH | TCRX |
|---|---|---|
| Founded | 1967 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0M | 63.6M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOMH | TCRX |
|---|---|---|
| Price | $2.93 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 65.7K | ★ 539.7K |
| Earning Date | 04-14-2026 | 03-04-2026 |
| Dividend Yield | ★ 22.18% | N/A |
| EPS Growth | ★ 39.75 | 12.28 |
| EPS | ★ 7.86 | N/A |
| Revenue | ★ $18,146,000.00 | $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $69.75 |
| P/E Ratio | $0.37 | ★ N/A |
| Revenue Growth | ★ 789.95 | 266.65 |
| 52 Week Low | $2.82 | $0.88 |
| 52 Week High | $8.40 | $2.57 |
Technical Indicators
Market Signals| Indicator | DOMH | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 45.34 |
| Support Level | $2.85 | $0.90 |
| Resistance Level | $3.56 | $1.24 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 10.14 | 19.23 |
Price Performance
Historical ComparisonAbout DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.